The two categories of mental health diagnosis that have grown the fastest in the past decade for working-age adults are high-functioning anxiety and adult attention deficit hyperactivity disorder. Both have generated a substantial body of self-help content, both have become common topics on therapy social media, and both are now diagnosed at multiples of the rate they were in the early 2010s. They also overlap on a meaningful list of symptoms, and a growing body of clinical literature suggests the misdiagnosis rate in primary care settings is higher than the field has been willing to discuss.
The presenting picture for both can include difficulty starting tasks, racing thoughts, restlessness, sleep disturbance, frequent procrastination followed by panicked productivity, irritability when interrupted, and a sense of mental overload. A patient describing those symptoms to a primary care doctor in a fifteen-minute appointment can leave with a diagnosis of generalized anxiety disorder, an ADHD diagnosis, or both, depending on the doctor's training and the patient's framing. Stimulant prescriptions for adults grew roughly 60% between 2018 and 2025. Anxiolytic prescriptions grew roughly 35% over the same period.
The clinical distinction matters because the treatments diverge sharply. ADHD is generally treated with stimulant medication, sometimes combined with non-stimulant medications and behavioral interventions. Anxiety is generally treated with SSRIs or SNRIs, sometimes with cognitive behavioral therapy and sometimes with short-term benzodiazepine bridging. Stimulants given to a patient whose underlying problem is anxiety can amplify the anxiety substantially. SSRIs given to a patient whose underlying problem is ADHD can flatten attention and motivation without addressing the cognitive core of the issue.
The mechanism that distinguishes the two clinically is the underlying driver of the inattention. ADHD inattention is rooted in dopamine and norepinephrine system differences. The patient cannot sustain attention because the reward salience system does not engage. Tasks that should feel motivating do not. Anxiety inattention is rooted in cognitive load. The patient cannot sustain attention on the task at hand because their working memory is occupied with worry, anticipated outcomes, and threat monitoring. The result looks the same on the outside. The cause is different.
The diagnostic standard for adult ADHD is more rigorous than most patients realize. The DSM-5 requires several inattentive or hyperactive symptoms present before age 12, persistent for at least six months, occurring in two or more settings, and causing significant impairment. The widely used self-report tools, including the ASRS, were developed as screening instruments and were not designed to be diagnostic on their own. A proper adult ADHD evaluation typically involves a structured clinical interview, ratings from a collateral informant who knew the patient as a child, and rule-outs for anxiety, depression, sleep disorders, and substance use that can mimic symptoms.
The high-functioning anxiety label, in contrast, is not a formal DSM-5 diagnosis. It is a colloquial framing for someone whose anxiety drives high external achievement while creating internal distress. Generalized anxiety disorder is the closest formal category, but the high-functioning framing captures the way anxiety can present in patients who never miss work, never miss a deadline, and would never describe themselves as struggling. The internal experience is restless dread, perfectionism, and chronic preoccupation with potential failure.
The differential matters most clearly when stimulants are on the table. A patient with anxiety-driven inattention placed on Adderall or Vyvanse often describes the first week as productive and focused, then gradually develops worsening sleep, increased irritability, weight loss they did not want, and a baseline anxiety that exceeds where they started. The pattern is consistent enough that experienced psychiatrists treat a poor stimulant trial as a useful diagnostic data point. A patient with true ADHD typically describes a stimulant trial as making the world feel quieter, not louder.